Racial differences in response to interferon-based antiviral therapy for hepatitis C virus infection: A hardwiring issue?

Journal of Infectious Diseases

Volumn 199, Issue 8, 2009, Pages 1101-1103

  Tai, Andrew W ^a   Chung, Raymond T ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; PEGINTERFERON; RIBAVIRIN; VIRUS RNA;

AFRICAN AMERICAN; ANTIVIRAL THERAPY; CAUCASIAN; CLINICAL TRIAL; DRUG BLOOD LEVEL; EDITORIAL; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INNATE IMMUNITY; PRIORITY JOURNAL; RACE DIFFERENCE; TREATMENT RESPONSE;

ANTIVIRAL AGENTS; CONTINENTAL POPULATION GROUPS; GENE EXPRESSION PROFILING; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; PHARMACOGENETICS;

EID: 65649125960     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/597385     Document Type: Editorial

References (15)

1. Di Bisceglie AM, Martin P, Kassianides C, et al.Recombinant interferon alfa therapy for chronic hepatitis C: a randomized, doubleblind, placebo-controlled trial. N Engl J Med 1989; 321:1506-10.
2. Davis GL, Balart LA, Schiff ER, et al.Treatment of chronic hepatitis C with recombinant interferon alfa: a multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med 1989; 321:1501-6.
3. Jeffers LJ, Cassidy W, Howell CD, Hu S, Reddy KR. Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology 2004; 39:1702-8.
4. Muir AJ, Bornstein JD, Killenberg PG. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. Atlantic Coast Hepatitis Treatment Group. N Engl J Med 2004; 350:2265-71.
5. Conjeevaram HS, Fried MW, Jeffers LJ, et al.Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 2006; 131:470-7.
6. Layden-Almer JE, Ribeiro RM, Wiley T, Perelson AS, Layden TJ. Viral dynamics and response differences in HCV-infected African Americans and white patients treated with IFN and ribavirin. Hepatology 2003; 37:1343-50.
7. Hoofnagle JH, Wahed AS, Brown RS Jr, Howell CD, Belle SH. Early changes in hepatitis C virus (HCV) levels in response to peginterferon and ribavirin treatment in patients with chronic HCV genotype 1 infection. Virahep-C Study Group. J Infect Dis 2009; 199:1112-20 (in this issue).
8. Howell CD, Dowling TC, Paul M, et al.Peginterferon pharmacokinetics in African American and Caucasian American patients with hepatitis C virus genotype 1 infection. Clin Gastroenterol Hepatol 2008; 6:575-83.
9. Feld JJ, Nanda S, Huang Y, et al.Hepatic gene expression during treatment with peginterferon and ribavirin: identifying molecular pathways for treatment response. Hepatology 2007; 46:1548-63.
10. Sarasin-Filipowicz M, Oakeley EJ, Duong FH, et al.Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci U S A 2008; 105:7034-9.
11. Foy E, Li K, Wang C, et al.Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science 2003; 300:1145-8.
12. Blindenbacher A, Duong FH, Hunziker L, et al.Expression of hepatitis c virus proteins inhibits interferon alpha signaling in the liver of transgenic mice. Gastroenterology 2003; 124: 1465-75.
13. Lin W, Choe WH, Hiasa Y, et al.Hepatitis C virus expression suppresses interferon signaling by degrading STAT1. Gastroenterology 2005; 128:1034-41.
14. Walsh MJ, Johnsson JR, Richardson MM, et al.Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signaling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1. Gut 2006; 55:529-35.
15. Huang Y, Feld JJ, Sapp RK, et al.Defective hepatic response to interferon and activation of suppressor of cytokine signaling 3 in chronic hepatitis C. Gastroenterology 2007; 132:733-44.